Zealand Pharma A/S has appointed Utpal Singh as chief scientific officer following a licensing deal with the Roche Group to co-develop a candidate drug for obesity. Dr Singh will lead the discovery and clinical translation of peptide medicines, including investment in data and computational science. He joins from Eli Lilly and Co where he led small molecule drug discovery. Dr Singh began his pharmaceutical career at Merck & Co Inc after completing a postdoctoral fellowship in organic chemistry at the Massachusetts Institute of Technology.
Zealand Pharma announced the appointment on 23 April 2025
Copyright 2025 Evernow Publishing Ltd